Want to see RXST full AI Analyst Report?

RxSight (RXST) Stock Forecast & Price Target

247 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RXST Analyst Ratings

Hold

1 Buy

6 Hold

1 Sell

Based on 8 analysts giving stock ratings to

RxSight

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RXST Stock 12 Month Forecast

Average Price Target

$8.04

▲(5.59% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for RxSight in the last 3 months. The average price target is $8.04 with a high forecast of $11.00 and a low forecast of $5.25. The average price target represents a 5.59% change from the last price of $7.61.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","6.5":"$6.5","11.5":"$11.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.035714285714286,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,6.5,9,11.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.17,5.618461538461538,6.066923076923077,6.515384615384615,6.963846153846154,7.412307692307692,7.860769230769231,8.30923076923077,8.757692307692308,9.206153846153846,9.654615384615385,10.103076923076923,10.551538461538462,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.17,5.39043956043956,5.610879120879121,5.831318681318681,6.051758241758242,6.272197802197803,6.492637362637363,6.713076923076923,6.933516483516484,7.153956043956045,7.374395604395605,7.594835164835166,7.815274725274726,{"y":8.035714285714286,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.17,5.176153846153846,5.182307692307692,5.188461538461539,5.194615384615385,5.200769230769231,5.2069230769230765,5.213076923076923,5.219230769230769,5.225384615384615,5.231538461538461,5.237692307692308,5.243846153846154,{"y":5.25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.7,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.01,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.79,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.65,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.83,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.34,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$11.00

Average Price Target$8.04

Lowest Price Target$5.25

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan Zimmerman

BTIG

$5.25

Hold

-31.01%

Downside

Reiterated

07/16/26

Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST), Kazia Therapeutics (NASDAQ: KZIA) and Crescent Biopharma (NASDAQ: CBIO)

Larry Biegelsen

Wells Fargo

Hold

18.27%

Upside

Reiterated

07/08/26

Wells Fargo Sticks to Its Hold Rating for RxSight (RXST)

Adam Maeder

Piper Sandler

$10

Hold

31.41%

Upside

Reiterated

07/07/26

Piper Sandler Keeps Their Hold Rating on RxSight (RXST)

Craig Bijou

Bank of America Securities

$8→$6.5

Sell

-14.59%

Downside

Reiterated

07/07/26

RxSight price target lowered to $6.50 from $8 at BofARxSight price target lowered to $6.50 from $8 at BofA

David Saxon

Needham

$11

Buy

44.55%

Upside

Reiterated

07/07/26

RxSight: Alcon Partnership and Margin Improvements Offset Near-Term Sales Shortfall; Buy Rating and $11 Price Target Reiterated

Young Li

Jefferies

$7.5→$6.5

Hold

-14.59%

Downside

Reiterated

07/07/26

RxSight price target lowered to $6.50 from $7.50 at JefferiesRxSight price target lowered to $6.50 from $7.50 at Jefferies

Steven Lichtman

William Blair

―

Hold

―

Reiterated

05/08/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Voyager Therapeutics (NASDAQ: VYGR), Alpha Teknova (NASDAQ: TKNO) and RxSight (NASDAQ: RXST)

Thomas Stephan

Stifel Nicolaus

$9→$8

Hold

5.12%

Upside

Reiterated

05/08/26

RxSight (RXST) Gets a Hold from Stifel Nicolaus

Patrick Wood

Morgan Stanley

$10

Hold

31.41%

Upside

Reiterated

03/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (NASDAQ: SLN), RxSight (NASDAQ: RXST) and Compass Therapeutics (NASDAQ: CMPX)

Danielle Antalffy

UBS

$8→$9

Hold

18.27%

Upside

Reiterated

02/26/26

RxSight price target raised to $9 from $8 at UBSRxSight price target raised to $9 from $8 at UBS

Robbie Marcus

J.P. Morgan

$8→$9

Sell

18.27%

Upside

Reiterated

11/06/25

RxSight price target raised to $9 from $8 at JPMorganRxSight price target raised to $9 from $8 at JPMorgan

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan Zimmerman

BTIG

$5.25

Hold

-31.01%

Downside

Reiterated

07/16/26

Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST), Kazia Therapeutics (NASDAQ: KZIA) and Crescent Biopharma (NASDAQ: CBIO)

Larry Biegelsen

Wells Fargo

Hold

18.27%

Upside

Reiterated

07/08/26

Wells Fargo Sticks to Its Hold Rating for RxSight (RXST)

Adam Maeder

Piper Sandler

$10

Hold

31.41%

Upside

Reiterated

07/07/26

Piper Sandler Keeps Their Hold Rating on RxSight (RXST)

Craig Bijou

Bank of America Securities

$8→$6.5

Sell

-14.59%

Downside

Reiterated

07/07/26

RxSight price target lowered to $6.50 from $8 at BofARxSight price target lowered to $6.50 from $8 at BofA

David Saxon

Needham

$11

Buy

44.55%

Upside

Reiterated

07/07/26

RxSight: Alcon Partnership and Margin Improvements Offset Near-Term Sales Shortfall; Buy Rating and $11 Price Target Reiterated

Young Li

Jefferies

$7.5→$6.5

Hold

-14.59%

Downside

Reiterated

07/07/26

RxSight price target lowered to $6.50 from $7.50 at JefferiesRxSight price target lowered to $6.50 from $7.50 at Jefferies

Steven Lichtman

William Blair

―

Hold

―

Reiterated

05/08/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Voyager Therapeutics (NASDAQ: VYGR), Alpha Teknova (NASDAQ: TKNO) and RxSight (NASDAQ: RXST)

Thomas Stephan

Stifel Nicolaus

$9→$8

Hold

5.12%

Upside

Reiterated

05/08/26

RxSight (RXST) Gets a Hold from Stifel Nicolaus

Patrick Wood

Morgan Stanley

$10

Hold

31.41%

Upside

Reiterated

03/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (NASDAQ: SLN), RxSight (NASDAQ: RXST) and Compass Therapeutics (NASDAQ: CMPX)

Danielle Antalffy

UBS

$8→$9

Hold

18.27%

Upside

Reiterated

02/26/26

RxSight price target raised to $9 from $8 at UBSRxSight price target raised to $9 from $8 at UBS

Robbie Marcus

J.P. Morgan

$8→$9

Sell

18.27%

Upside

Reiterated

11/06/25

RxSight price target raised to $9 from $8 at JPMorganRxSight price target raised to $9 from $8 at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

KURAKura Oncology

CSTLCastle Biosciences

VKTXViking Therapeutics

ATECAlphatec Holdings

TRVITrevi Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering RxSight

3 Months

David SaxonNeedham

Success Rate

14/32 ratings generated profit

Average Return

+3.63%

Copying David Saxon's trades and holding each position for 3 Months would result in 43.75% of your transactions generating a profit, with an average return of +3.63% per trade.

1 Year

David SaxonNeedham

Success Rate

13/32 ratings generated profit

Average Return

+23.11%

Copying David Saxon's trades and holding each position for 1 Year would result in 40.63% of your transactions generating a profit, with an average return of +23.11% per trade.

2 Years

David SaxonNeedham

Success Rate

8/32 ratings generated profit

Average Return

+15.35%

Copying David Saxon's trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of +15.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RXST Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RXST has received 2 Buy Ratings, 8 Hold Ratings, and 2 Sell Ratings. RXST average Analyst price target in the past 3 months is 8.04.

Each month's total comprises the sum of three months' worth of ratings.

RXST Financial Forecast

RXST Earnings Forecast

Next quarter’s earnings estimate for RXST is -$0.35 with a range of -$0.40 to -$0.30. The previous quarter’s EPS was -$0.38. RXST beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year RXST has Performed in-line its overall industry.

RXST Sales Forecast

Next quarter’s sales forecast for RXST is $32.47M with a range of $31.40M to $33.22M. The previous quarter’s sales results were $30.89M. RXST beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year RXST has Performed in-line its overall industry.

RXST Stock Forecast FAQ

What is RXST’s average 12-month price target, according to analysts?

Based on analyst ratings, Rxsight, Inc.’s 12-month average price target is 8.04.

What is RXST’s upside potential, based on the analysts’ average price target?

Rxsight, Inc. has 5.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RXST a Buy, Sell or Hold?

Rxsight, Inc. has a consensus rating of Hold which is based on 1 buy ratings, 6 hold ratings and 1 sell ratings.

What is Rxsight, Inc.’s price target?

The average price target for Rxsight, Inc. is 8.04. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $5.25. The average price target represents 5.59% Increase from the current price of $7.61.

What do analysts say about Rxsight, Inc.?

Rxsight, Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of RXST?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

RxSight (RXST) Stock Forecast & Price Target

RXST Analyst Ratings

RXST Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering RxSight

RXST Analyst Recommendation Trends

RXST Financial Forecast

RXST Earnings Forecast

RXST Sales Forecast

RXST Stock Forecast FAQ

Detailed List of Analyst Forecasts